Stock TUB FINANCIÈRE DE TUBIZE S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Financière de Tubize S.A.

Equities

TUB

BE0003823409

Pharmaceuticals

Market Closed - Euronext Bruxelles
Other stock markets
 11:35:10 2024-04-26 am EDT 		5-day change 1st Jan Change
94.6 EUR +1.83% Intraday chart for Financière de Tubize S.A. +2.94% +31.94%
Mar. 27 Financière de Tubize SA Announces Board Resignations CI
Mar. 16 Financière de Tubize SA Proposes Gross Dividend, Payable on 3 May 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,704 2,827 3,677 4,019 3,151 3,192
Enterprise Value (EV) 1 2,846 2,913 3,709 4,024 3,198 3,270
P/E ratio 9.48 x 9.96 x 14.1 x 10.6 x 37 x 36.2 x
Yield 0.92% 0.98% 0.82% 0.83% 1.21% 1.35%
Capitalization / Revenue - - - - 386,638,687,032 x -
EV / Revenue - - - - 392,371,878,420 x -
EV / EBITDA - - - - - -
EV / FCF -1,487 x -1,888 x -2,405 x -8,116 x -1,352 x -1,173 x
FCF Yield -0.07% -0.05% -0.04% -0.01% -0.07% -0.09%
Price to Book 1.16 x 1.06 x 1.32 x 1.24 x 1.8 x 1.78 x
Nbr of stocks (in thousands) 44,549 44,513 44,513 44,513 44,513 44,513
Reference price 2 60.70 63.50 82.60 90.30 70.80 71.70
Announcement Date 2/28/19 2/20/20 2/27/21 2/26/22 3/18/23 3/15/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - 0.008151 -
EBITDA - - - - - -
EBIT 1 -0.825 -0.993 -2.249 -1.357 -1.823 -2.079
Operating Margin - - - - -22,362.69% -
Earnings before Tax (EBT) 1 285.2 283.7 260.5 380.1 85.17 88.15
Net income 1 285.2 283.7 260.5 380.1 85.17 88.15
Net margin - - - - 1,044,901.09% -
EPS 2 6.401 6.374 5.853 8.539 1.913 1.980
Free Cash Flow 1 -1.914 -1.543 -1.542 -0.4958 -2.366 -2.789
FCF margin - - - - -29,023.51% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.5600 0.6200 0.6800 0.7500 0.8600 0.9700
Announcement Date 2/28/19 2/20/20 2/27/21 2/26/22 3/18/23 3/15/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 142 86.5 32.6 4.14 46.7 78.6
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.91 -1.54 -1.54 -0.5 -2.37 -2.79
ROE (net income / shareholders' equity) 12.8% 11.3% 9.55% 12.6% 4.93% 4.97%
ROA (Net income/ Total Assets) -0.02% -0.02% -0.05% -0.03% -0.06% -0.07%
Assets 1 -1,326,307 -1,197,063 -517,930 -1,367,230 -134,550 -127,571
Book Value Per Share 2 52.50 59.90 62.80 73.00 39.30 40.40
Cash Flow per Share 2 0.0300 0.0100 0.0200 0.3600 0.0200 0.0100
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 2/28/19 2/20/20 2/27/21 2/26/22 3/18/23 3/15/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
94.6 EUR
Average target price
118.2 EUR
Spread / Average Target
+25.00%
Consensus

Sector Other Pharmaceuticals

1st Jan change Capi.
FINANCIÈRE DE TUBIZE S.A. Stock Financière de Tubize S.A.
+31.94% 4.5B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TUB Stock
  4. Financials Financière de Tubize S.A.